Rebalix
Invesco · sheet of 10 September 2026
Invesco · sheet of 10 September 2026ETF sheet · official issuer and register data
Invesco STOXX Europe 600 Optimised Health Care UCITS ETF Acc
XDPS · IE00B5MJYY16 · class Acc · EUR · domicile Ireland
Equity · Europe · Health careSFDR art. 6
Index tracked: STOXX® Europe 600 Optimised Health Care Total Return (Net) Index
- TER
- 0.20%+ trans. 0.00%
- Fund size
- 11 m EUR
- Tracking difference
- −0.17%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Synthetic (swap)
- Income
- Accumulating
Launch 8 Jul 2009 · costs from the KID as of 14 Aug 2026 · 99 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 14 Aug 2026
Investment objective: The objective of the Fund is to achieve the net total return performance of the STOXX Europe 600 Optimised Health Care Index (the "Index"), less fees, expenses and transaction costs.
Redemption and Dealing of Shares:
The Fund's shares are listed on one or more Stock Exchange(s). Investors can buy or sell shares daily through an intermediary directly or on Stock Exchange(s) on which the shares are traded. In exceptional circumstances investors will be permitted to redeem their shares directly from the Umbrella Fund in accordance…
Performance since series start (in euro) — base 100
8 Jul 2009 → 13 Aug 2026 · dividends reinvested where declared by the issuer
Returns in euro
| 1 year | +13.2% |
| 3 years | +13.4% |
| 5 years | +19.7% |
| 10 years | +81.8% |
| Since series start | +425.2% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 16.05% | 14.85% | 14.79% |
| Max drawdown | −12.85% | −21.48% | −21.48% |
| Sharpe | 0.20 | 0.06 | 0.10 |
| Sortino | 0.31 | 0.09 | 0.14 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · XDPS · IE00B5MJYY161
RebalixXDPS · IE00B5MJYY16 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +7.78% | +7.96% | −0.18% |
| 2024 | +7.34% | +7.49% | −0.15% |
| 2023 | +5.90% | +6.09% | −0.18% |
| 2022 | −7.61% | −7.45% | −0.15% |
| 2021 | +25.23% | +25.61% | −0.37% |
Holdings
Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 31 Aug 2026 · 99 securities · top-10 weight = 33.1%
| Top holdings | Weight |
|---|---|
| 4.5% | |
| 4.1% | |
| 4.0% | |
| 3.6% | |
| 3.5% | |
| 3.2% | |
| 2.7% | |
| 2.6% | |
| 2.5% | |
| 2.5% |
Listing venues
ESMA register (FIRDS) and official exchange lists
— · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange
XDPS · Xetra (Deutsche Börse)
+ 15 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00B5MJYY16
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00B5MJYY16
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · XDPS · IE00B5MJYY162